Aytu BioPharma (AYTU) Competitors

Aytu BioPharma (NASDAQ:AYTU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Do analysts prefer AYTU or VRCA?

Aytu BioPharma presently has a consensus price target of $10.00, suggesting a potential upside of 280.23%. Verrica Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 21.03%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Verrica Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Do insiders and institutionals have more ownership in AYTU or VRCA?

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 3.6% of Aytu BioPharma shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, AYTU or VRCA?

Aytu BioPharma has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Does the media favor AYTU or VRCA?

In the previous week, Aytu BioPharma and Aytu BioPharma both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Aytu BioPharma's score of 0.94 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is AYTU or VRCA more profitable?

Aytu BioPharma has a net margin of 2.37% compared to Verrica Pharmaceuticals' net margin of 0.00%. Aytu BioPharma's return on equity of 3.51% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	2.37%	3.51%	0.91%
Verrica Pharmaceuticals	N/A	N/A	-145.63%

Which has preferable earnings and valuation, AYTU or VRCA?

Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$81.66M	0.29	-$15.84M	-$0.72	-3.65
Verrica Pharmaceuticals	$7.18M	85.16	-$76.58M	-$1.20	-5.51

Summary

Aytu BioPharma beats Verrica Pharmaceuticals on 10 of the 15 factors compared between the two stocks.